Poster Presentations Session V
Poster Presentations Session V Wednesday, 2 November 2016
POSTERS SET-UP: 8:30 - 8:45
POSTERS DISPLAY HOURS: 8:45 - 13:45
POSTER AUTHOR DISCUSSION: 12:45 - 13:45
POSTERS DISMANTLE: 13:45


Poster display locations are shown below the poster codes
MEDICAL DEVICE/DIAGNOSTICS - Clinical Outcomes Studies
PMD1
A1
HEALTH TECHNOLOGY ASSESSMENT ON CONTINUOUS AND INTERMITTENT RENAL REPLACEMENT THERAPIES FOR ACUTE KIDNEY INJURY IN ADULT PATIENTS
Schoenfelder T, Chen X, Bleß H
IGES Institut GmbH, Berlin, Germany

PMD2
A2
IMPLEMENTATION OF ONE STOP DIAGNOSIS IN PATIENTS WITH THYROID NODULES: IMPACT ON COST AND SURGERY
Kandel M1, Schlumberger M2, Benhamou E2, Leboulleux S2, Berdelou A2, Pottier E2, Suciu V2, Borget I3
1Gustave Roussy, PARIS, France, 2Gustave Roussy, Villejuif, France, 3Institut Gustave Roussy, Villejuif, France

PMD3
A3
SYSTEMATIC REVIEW AND META-ANALYSIS OF ACCURACY OF DIAGNOSTIC TESTS FOR SCREEN DETECTION OF ATRIAL FIBRILLATION
Thom H1, McAleenan A1, Davies P1, Okoli GN1, Higgins J1, Hollingworth W1, Sterne J1, Feder G1, Eaton D2, Hingorani A3, Fawsitt C1, Lobban T4, Bryden PA5, Richards A1, Sofat R3, Welton NJ1
1University of Bristol, Bristol, UK, 2Anticoagulation Europe, Kent, UK, 3University College London, London, UK, 4Atrial Fibrillation Association, Warwickshire, UK, 5Roche, Basel, Switzerland

PMD4
A4
EVALUATION OF BREAST CANCER HER2 STATUS ACCURACY USING A PREDICTIVE MODEL BASED ON HER-FRANCE REAL WORLD NATIONAL DATABASE
Egele C1, Pau D2, Rabut J3, Fetique D1, Martin J2, Dupin J4, Bellocq J5
1CHRU Strasbourg, Strasbourg, France, 2Roche, Boulogne-Billancourt, France, 3Lincoln Systems, Boulogne-Billancourt, France, 4ITM stat, Neuilly/seine, France, 5Hospital of Strasbourg, Strasbourg, France

PMD5
A5
THE 21-GENE ASSAY IN THE DECISION IMPACT ASSESSMENT OF ER+, HER2- BREAST CANCER: A FRENCH REAL LIFE PROSPECTIVE STUDY
Mouysset J1, Laplaige P2, Fignon A3, Jallais L4, Lafuma A5, Michaud P6, Dohollou N7, Gligorov J8
1Clinique Rambot-Provençale, Aix en Provence, France, 2Polyclinique de Blois, La Chaussee St Victor, France, 3Clinique de l'Alliance, St-Cyr-sur-Loire, France, 4Tours, Tours, France, 5Cemka-Eval, Bourg La Reine, France, 6OncoCentre, Orleans, France, 7Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France, 8APHP, Tenon Hospital, Paris, France

PMD6
A6
DATA MINING USED TO CHARACTERIZE DISCORDANCE IN GASTRIC CANCERS HER2 STATUS DETERMINATION TO HELP FOR A BETTER TREATMENT DECISION
Pau D1, Monges G2, Doucet L3, Terris B4, Chenard M5, Bibeau F6, Penault-Llorca F7, Martin J1, Rabut J8, Leroux D9
1Roche, Boulogne-Billancourt, France, 2Hôpital Pasteur, Nice, France, 3Hôpital Cavale Blanche, Brest, France, 4Hôpital Cochin, Paris, France, 5Hôpital Hautepierre, Strasbourg, France, 6Institut du Cancer de Montpellier, Montpellier, France, 7Centre Jean Perrin, Clermont-Ferrand, France, 8Lincoln Systems, Boulogne-Billancourt, France, 9HAYS PHARMA, Paris, France

PMD7
A7
THE STOOL ANTIGEN TEST FOR DETECTION OF HELICOBACTER PYLORI FOR DIAGNOSE H.PYLORI INFECTION AND ASSESSMENT OF ERADICATION THERAPY
Galiyeva A
Astana Medical University, Astana, Kazakhstan

PMD8
A8
ASSESSMENT OF PET/CT USE IN RADIOTHERAPY PLANNING VERSUS CT SCANS USE ONLY
Jerabkova S1, Pangracova L2
1University of Economics, Prague, Prague, Czech Republic, 2Czech Technical University, Kladno, Czech Republic

PMD9
A9
QUICK ASSESSMENT ON LUNG CANCER SCREENING WITH LOW-DOSE COMPUTED TOMOGRAPHY
Laschkolnig A, Pertl D
Gesundheit Österreich GmbH, Vienna, Austria

PMD10
A10
ADDED BENEFIT OF UPPER AIRWAY STIMULATION FOR THE TREATMENT OF MODERATE TO SEVERE OBSTRUCTIVE SLEEP APNEA IN AUSTRIA
Pietzsch JB1, Zauner G2, Liu S1
1Wing Tech Inc., Irvine, CA, USA, 2dwh GmbH, Vienna, Austria

PMD11
A11
CLINICAL IMPACT OF ANTIMICROBIAL IMPREGNATED CATHETERS FOR PREVENTION OF INFECTION IN CEREBROSPINAL FLUID DIVERSION PROCEDURES
Parker E1, Velleca M2, Scagliarini L2
1DePuy Synthes, Leeds, UK, 2Johnson & Johnson Medical S.p.A., Pratica di Mare, Italy

PMD12
A12
TRANSCATHETER AORTIC VALVE IMPLANTATION FOR INOPERABLE SEVERE AORTIC STENOSIS - A META-ANALYSIS
Mattos AZ1, Schroder DA2, Colpani V3, Restelatto LM4, Ribeiro RA5
1PUC-RS, Porto Alegre, Brazil, 2Hospital de Caridade de Ijuí, Ijuí, Brazil, 3IMED - Faculdade Meridional, Passo Fundo, Brazil, 4Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, 5IMED - Faculdade Meridional and Fundação IMED, Passo Fundo, Brazil

PMD13
A13
ASSESSMENT OF CAROTID STENTING SAFETY: A FRENCH EXHAUSTIVE COHORT STUDY BASED ON THE RE-USE OF ROUTINE NATIONAL HEALTH DATABASE
Marque S1, Beyssen B2, Congard-Chassol B3, Levesque K4, Nguyen T5, Mouton E6, Collignon C7, Chatellier G2
1EXEPI, Paris, France, 2HEGP, Paris, France, 3SNITEM, Levallois, France, 4Capionis, Bordeaux, France, 5Johnson & Johnson Medical Devices, ISSY-LES-MOULINEAUX, France, 6Boston Scientific, Nanterre, France, 7Medtronic, Boulogne, France

PMD14
A14
WITHDRAWN

PMD15
A15
THE PREDIRTION OF THE BRCA1/2-RELATED OVARIAN CANCER MORBILITY IN RUSSIA
Ryazhenov VV1, Gorokhova SG2
1I.M. Sechenov First Moscow State Medical University, Moscow, Russia, 2Research Clinical Center of JSC Russian Railways, Moscow, Russia

MEDICAL DEVICE/DIAGNOSTICS - Cost Studies
PMD16
A16
WITHDRAWN

PMD17
A17
DIFFUSION OF TRANS-ARTERIAL RADIOEMBOLIZATION FOR THE TREATMENT OF INTERMEDIATE-ADVANCED HEPATOCELLULAR CARCINOMA IN ITALY: A BUDGET IMPACT ANALYSIS
Rognoni C, Ciani O, Sommariva S, Tarricone R
Bocconi University, Milan, Italy

PMD18
A18
BUDGET IMPACT ANALYSIS OF CEMENTLESS VERSUS CEMENTED PROSTHESES FOR TOTAL HIP ARTHROPLASTY FROM A UK HOSPITAL PERSPECTIVE
Taylor H1, Muehlendyck C2, Peden S1
1Johnson & Johnson Medical Limited, Leeds, UK, 2Johnson & Johnson Medical GmbH, Norderstedt, Germany

PMD19
A19
INVESTIGATING THE ECONOMIC IMPACT OF SFLT-1/PLGF RATIO AS A PREDICTIVE TEST IN WOMEN WITH SUSPECTED PREECLAMPSIA IN ITALY
Paolini D1, Dionisi M1, Frusca T2, Gervasi MT3, Boscaini S1, Cetin I4
1Roche Diagnostics S.p.A., Monza, Italy, 2University of Parma, Parma, Italy, 3Hospital of Padova, Padova, Italy, 4University of Milan, Milan, Italy

PMD20
A20
ECONOMIC BURDEN OF MAINTAINING VASCULAR ACCESS PATENCY IN PATIENTS WITH HEMODIALYSIS FISTULAS : A NATIONAL POPULATION-BASED STUDY
Choi H, Lim A
Medtronic Korea, Ltd., Seoul, South Korea

PMD21
A21
BUDGET IMPACT MODEL TO AUGMENT THE VALUE OF AN INNOVATIVE DEVICE FOR THE EARLY DETECTION OF PRESSURE ULCERS IN SCOTLAND
Zanin A1, Marty R1, Akpo H1, Burns M2
1Deloitte, Diegem, Belgium, 2Bruin Biometrics LLC, Los Angeles, CA, USA

PMD22
A22
THE POTENTIAL TO IMPROVE INHALATION TECHNIQUE IN PATIENTS WITH ASTHMA OR COPD BY SWITCHING FROM SYMBICORT® TURBUHALER® (BUDESONIDE + FORMOTEROL) TO DUORESP® SPIROMAX®: ESTIMATED IMPACT ON THE NUMBER AND COST OF UNSCHEDULED HEALTHCARE EVENTS IN POLAND
Watson A1, Bijos P2, Ludwikowski R2, Lewis A1, Blackney M1, Torvinen S3, Plich A3
1Covance Market Access, London, UK, 2Teva Pharmaceuticals Polska, Warszawa, Poland, 3Teva Pharmaceuticals Europe B.V., Amsterdam, The Netherlands

PMD23
A23
COST OF EBOLA VIRUS DISEASE DIAGNOSIS USING RAPID POINT-OF-CARE DIAGNOSTICS IN SIERRA LEONE
Evans JS, Hearmon NC, Beale RC, Marsh W
Costello Medical Consulting Ltd, Cambridge, UK

PMD24
A24
THE ECONOMIC IMPACT OF USING ANTIMICROBIAL CATHETERS IMPREGNATED WITH RIFAMPICIN AND CLINDAMYCIN TO PREVENT INFECTION IN EXTERNAL VENTRICULAR DRAINAGE: A BUDGET IMPACT ANALYSIS
Mercurio M1, Paragò V1, Velleca M1, Scagliarini L1, Parker E2, Garziera G1
1Johnson & Johnson Medical S.p.A., Pratica di Mare, Italy, 2DePuy Synthes, Leeds, UK

PMD25
A25
ECONOMIC ANALYSES OF FLAIR® AND FLUENCY® PLUS ENDOVASCULAR STENT GRAFTS FOR THE TREATMENT OF VASCULAR ACCESS STENOSIS: A U.S. HOSPITAL AND PAYER PERSPECTIVE
Barclay B1, Hogan A2, Hollmann S2, Ferko N2, Delatore P3
1C.R. Bard Inc., Murray Hill, NJ, USA, 2Cornerstone Research Group Inc., Burlington, ON, Canada, 3CR Bard Inc., Murray Hill, NJ, USA

PMD26
A26
BUDGET IMPACT ANALYSIS OF THE PERMANENT ENDOVASCULAR ADHESIVE CLOSURE SYSTEM IN THE TREATMENT OF VENOUS REFLUX AND CHRONIC VENOUS INSUFFICIENCY (CVI) IN TURKEY
Ozdemir Saltik Z, Akgul T, Can H, Copur F, Askin E
Medtronic, Istanbul, Turkey

PMD27
A27
BUDGET IMPACT ANALYSIS OF NATIONAL CERVICAL CANCER SCREENING PROGRAM IN DENMARK: CYTOLOGY WITH HPV TRIAGE VS. HPV PRIMARY SCREENING WITH REFLEX CYTOLOGY TRIAGE & CINTEC PLUS CYTOLOGY
Kempers J1, Narvestad J2, Kofod M2, Mikkelsen RM2, Ersek K1
1Roche Diagnostics, Almere, The Netherlands, 2Roche Diagnostics, Hvidovre, Denmark

PMD28
A28
INCREASED CLINICAL AND ECONOMIC BENEFIT IN SPAIN ASSOCIATED WITH IMPROVEMENT TO ±8.5% OF THE ACCURACY OF GLUCOSE METERS ADAPTED TO THE CURRENT ISO 15197:2013 (±15%)
Sanz-Granda Á1, Artola-Menéndez S2, Franch-Nadal J3, Mata-Cases M3, Merino-Torres JF4
1Proyectos de Farmacoeconomía, Navacerrada (Madrid), Spain, 2CS José Marvá, Madrid, Spain, 3Fundación redGPDS, DAP_CAT, Barcelona, Spain, 4Hospital Universitari i Politècnic La Fe, Valencia, Spain

PMD29
A29
BUDGET IMPACT OF CONTINUOUS SUBCUTANEOUS INSULIN INFUSION COMPARED WITH MULTIPLE DAILY INSULIN INJECTIONS FOR THE TREATMENT OF TYPE 1 DIABETES IN SPAIN
Elías I1, Giménez M2, Álvarez M1, Quirós C2, Conget I2
1Medtronic Ibérica, S.A., Madrid, Spain, 2Diabetes Unit. Endocrinology Department. Hospital Clínic i Universitari de Barcelona. IDIBAPS, Barcelona, Spain

PMD30
A30
ECONOMIC VALUE OF EPTFE STENT-GRAFTS COMPARED TO BALLOON ANGIOPLASTY FOR TREATING THROMBOSED AND DYSFUNCTIONAL ARTERIOVENOUS GRAFTS IN ENGLAND
Mohr BA1, Evans RM2
1W. L. Gore & Associates, Inc., Flagstaff, AZ, USA, 2W.L. Gore & Associates (UK) Limited, Livingston, UK

PMD31
A31
A REAL WORLD COST ANALYSIS OF SERUM HBSAG QUANTIFICATION TEST IN PATIENTS WITH CHRONIC HEPATITIS B: THE CASE OF THE UNIVERSITY OF NAPLES FEDERICO II
Aiello A1, Guarino M2, D'Ausilio A1, Latorre E1, Toumi M3, Caporaso N2, Morisco F2
1Creativ Ceutical, Milano, Italy, 2University of Naples "Federico II", Naples, Italy, 3Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Université de la Méditerranée, Marseille, France

PMD32
A32
ECONOMIC ANALYSIS OF ENDOVASCULAR INTERVENTIONS FOR THE TREATMENT OF FEMOROPOPLITEAL PERIPHERAL ARTERY DISEASE IN AUSTRIA
Pietzsch JB1, Geisler BP1, Jaff MR2, Zeller T3, Brodmann M4
1Wing Tech Inc., Irvine, CA, USA, 2Harvard University, Boston, MA, USA, 3Universitaets-Herzzentrum Freiburg Bad Krozingen, Bad Krozingen, Germany, 4Medizinische Universtität Graz, Graz, Austria

PMD33
A33
A COST-MINIMIZATION ANALYSIS OF DERMATOPHYTE TEST KIT WITH TINEA UNGUIUM UNDER HEALTH CARE SYSTEM IN JAPAN
Watanabe R1, Igarashi A2, Wakamoto H3, Osawa H3
1Tokyo Medical University, Tokyo, Japan, 2University of Tokyo, Graduate School of Pharmaceutical Sciences, Tokyo, Japan, 3JNC Corporation, Tokyo, Japan

PMD34
A34
BUDGET IMPACT ANALYSIS OF A FLASH GLUCOSE MONITORING SYSTEM FOR PATIENTS WITH DIABETES WHO ARE USING INTENSIVE INSULIN
Hellmund R
Abbott Diabetes Care, Alameda, CA, USA

PMD35
A35
OPEN VERSUS ENDOVASCULAR REPAIR IN PATIENTS WITH ABDOMINAL AORTIC ANEURYSM IN SPAIN ─ A COST COMPARISSON
Egea M1, Fernandez-Samos R2, Lechón JA3, Reparaz LM4, Álvarez M5, Cairols M6
1Medtronic Iberica, Madrid, Spain, 2Complejo Asistencial Universitario de León, León, Spain, 3Hospital Universitario Miguel Servet, Zaragoza, Spain, 4Hospital Universitario Gregorio Marañón, Madrid, Spain, 5Medtronic Ibérica, Madrid, Spain, 6Hospital Delfos, Barcelona, Spain

PMD36
A36
DAY SURGERY VS REGULAR ADMISSION: ACTIVITY-BASED COST ANALYSIS OF PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY (PTCA) PROCEDURES FROM HOSPITAL PERSPECTIVE
Monti F, Boggi A, Colantonio R, Rotolo FL, Bruno E, Serdoz R
San Pietro FBF Rome hospital, Rome, Italy

PMD37
A37
ECONOMIC BURDEN OF COLORECTAL RESECTIONS: INCREMENTAL EFFECTS IN CANCER PATIENTS
Yoo A1, Hsiao C2, Cheng H2, Kalsekar I1
1Johnson & Johnson Co., New Brunswick, NJ, USA, 2Global Health Economics and Market Access, Ethicon Inc., Cincinnati, OH, USA

PMD38
A38
INCREMENTAL BURDEN OF CANCER IN PATIENTS UNDERGOING HEPATIC RESECTIONS: RESULTS FROM A NATIONAL HOSPITAL BILLING DATA
Kalsekar I1, Hsiao C2, Cheng H2, Yoo A3
1Johnson & Johnson Co., New Brunswick, NJ, USA, 2Global Health Economics and Market Access, Ethicon Inc., Cincinnati, OH, USA, 3Medical Device - Epidemiology, Johnson and Johnson, New Brunswick, NJ, USA

PMD39
B1
A RETROSPECTIVE PREMIER DATABASE STUDY TO EVALUATE DIFFERENCES BETWEEN PROGEL™ PLEURAL AIR LEAK SEALANT AS COMPARED WITH OTHER SEALANTS IN THE INPATIENT SURGICAL SETTING
Mortman K1, Corral M2, Zhang X2, Berhane I2, Bourque M3, Ferko N3
1George Washington University Hospital, Washington, DC, USA, 2C.R. Bard Inc., Murray Hill, NJ, USA, 3Cornerstone Research Group Inc., Burlington, ON, Canada

PMD40
B2
MICRO-COSTING ANALYSIS OF PROCEDURES ON VARICOSE VEINS PERFORMED IN OUTPATIENT SETTING
Baccaglini U, Pavei P
AOU Padova, Padova, Italy

PMD41
B3
PRELIMINARY COST-EFFECTIVENESS ASSESSMENT OF 3D PRINTED ANATOMIC MODELS FOR CONGENITAL HEART DISEASES
Tack P1, Annemans L2
1Ghent University, Ghent, Belgium, 2Ghent University - Brussels University, Ghent, Belgium

PMD42
B4
COST PATTERNS IN PATIENTS TREATED WITH SPINAL CORD STIMULATION FOLLOWING SPINE SURGERY—A REGISTER BASED STUDY
Hansson-Hedblom A1, Jonsson E1, Kirketeig T2, Hägg O3, Fritzell P4, Borgström F1
1Quantify Research, Stockholm, Sweden, 2Department of Surgical Sciences, Uppsala University Hospital, Uppsala, Sweden, 3Spine Center Göteborg, Gothenburg, Sweden, 4Capio St Göran Hospital, Stockholm, Sweden

PMD43
B5
DIRECT HEALTHCARE COSTS AND CLINICAL OUTCOMES OF OPEN ABDOMINAL AORTIC ANEURYSM REPAIR IN SPAIN. RECAPTA STUDY
Egea M1, Fernandez-Samos R2, Lechón JA3, Reparaz LM4, Álvarez M5, Cairols M6
1Medtronic Iberica, Madrid, Spain, 2Complejo Asistencial Universitario de León, León, Spain, 3Hospital Universitario Miguel Servet, Zaragoza, Spain, 4Hospital Universitario Gregorio Marañón, Madrid, Spain, 5Medtronic Ibérica, Madrid, Spain, 6Hospital Delfos, Barcelona, Spain

PMD44
B6
A PROPENSITY SCORE MATCHED STUDY OF PLASMABLADE VS COBLATION TECHNOLOGY DURING PEDIATRIC TONSILLECTOMY AND ADENOIDECTOMY PROCEDURES
Nichols CI, Vose JG
Medtronic Advanced Energy, Portsmouth, NH, USA

PMD45
B7
ECONOMIC BENEFITS OF CPAP TREATMENT FOR OBSTRUCTIVE SLEEP APNEA IN THE ELDERLY
Park SS, Menzin J
Boston Health Economics, Waltham, MA, USA

PMD46
B8
COST-EFFECTIVENESS OF EARLY TIPS WITH EXPANDED POLYTETRAFLUOROETHYLENE (EPTFE) COVERED STENT-GRAFTS COMPARED TO ENDOSCOPIC PROCEDURES TO MANAGE ACUTE VARICEAL BLEEDING – A SPANISH SCENARIO
Pérez-Mitru A1, Villacampa Lordan A1, Scarpa F2
1Oblikue Consulting, Barcelona, Spain, 2W.L.GORE & Associates, Verona, Italy

PMD47
B9
COST-EFFECTIVENESS EVALUATION OF TIPS PROCEDURES WITH EXPANDED POLYTETRAFLUOROETHYLENE (EPTFE) COVERED STENT-GRAFTS COMPARED TO LARGE VOLUME PARACENTESIS IN PATIENTS WITH REFRACTORY ASCITES – A SPANISH SCENARIO
Pérez-Mitru A1, Villacampa Lordan A1, Scarpa F2
1Oblikue Consulting, Barcelona, Spain, 2W.L.GORE & Associates, Verona, Italy

PMD48
B10
COST ANALYSIS OF HUMAN GENOME SEQUENCING IN CANCER DIAGNOSIS IN FRANCE: NEXT GENERATION SEQUENCING
Kossi DS1, Touzani R2, Borget I3, Zhaomin Z4, Vaur D5, Rouleau E6, Preudhomme C7, Lacroix L4, Perrier L8, Durand-Zaleski I9, Marino P2, Baffert S1
1Fondation Ophtalmologique Adolphe de Rothschild, Paris, France, 2Institut Paoli Calmettes, Marseille, France, 3Univ Paris-Sud, Faculty of Pharmacy, GRADES, Châtenay-Malabry, France, 4Institut Gustave Roussy, Villejuif, France, 5Centre François Baclesse-Inserm U1079 - Génétique du cancer et Maladies Neuropsychiatriques, Caen, France, 6Institut Curie, Paris, France, 7CHRU de Lille - Centre de Biologie Pathologie Génétique, Lille, France, 8Cancer Centre Leon Berard, Lyon, France, 9URC Eco, Paris, France

PMD49
B11
COST-BENEFIT ANALYSIS FOR DIRECT VISUAL OBSERVATION OF NASOGASTRIC ENTERAL FEEDING TUBE PLACEMENT
Saunders R1, Ozols A2
1Coreva Scientific, Freiburg im Breisgau, Germany, 2Medtronic, Boulder, CO, USA

PMD50
B12
COST-BENEFIT ANALYSIS OF DENTAL PROSTHESIS IN UKRAINE
Got S, Zaliskyy O, Zaliska O
Danylo Halytsky Lviv National Medical University, Lviv, Ukraine

PMD51
B13
EVALUATING THE COST-BENEFIT OF A COGNITIVE ASSESSMENT AND TRAINING PROGRAM ACROSS A SMART CITY POPULATION IN THE UK
Sparrowhawk K1, Cliveden P1, Ratto M1, Ogle-Welbourn W2, Sunley A2
1MyCognition, London, UK, 2Peterborough City Council, Peterborough, UK

PMD52
B14
POTENTIAL COST SAVINGS OF A POINT-OF-CARE DIAGNOSTIC TEST MEASURING ANTIPSYCHOTIC PLASMA LEVELS FOR TREATMENT OF PATIENTS WITH SCHIZOPHRENIA IN SPAIN
Pobre MA1, Riley R2, Predmore Z3, Horvitz-Lennon M3, Mattke S3
1Johnson & Johnson Medical, Madrid, Spain, 2Janssen Diagnostics, Titusville, NJ, USA, 3RAND Health, Boston, MA, USA

PMD53
B15
COST-EFFECTIVENESS OF RADIAL ACCESS VERSUS FEMORAL FOR DIAGNOSTIC CARDIAC CATHETERIZATION AND CORONARY INTERVENTION IN COLOMBIA
Borja H1, Gil-Rojas Y2, Castañeda-Cardona C3, Rosselli D2
1Universidad de Antioquia, Medellín, Colombia, 2Pontificia Universidad Javeriana, Bogota, Colombia, 3Neuroeconomix, Bogota, DC, Colombia

PMD54
B16
COST - EFFECTIVENESS ANALYSIS OF PRESEPSIN COMPARED WITH C-REACTIVE PROTEIN AND PROCALCITONIN IN DETECTING SEVERE BACTERIAL INFECTION IN CHILDREN AGED 29 DAYS TO 36 MONTHS OLD WITH FEVER WITHOUT SOURCE
Amastha J, Berdejo L, Acosta-Reyes J
Universidad del Norte, Barranquilla, Colombia

PMD55
B17
COST-EFFECTIVENESS OF DIFFERENT CERVICAL CANCER PRIMARY SCREENING USING CYTOLOGY, HPV OR P16/KI-67 TESTING ALONE OR IN COMBINATIONS FOR THE AUSTRIAN HEALTH CARE CONTEXT
Sroczynski G1, Esteban E1, Widschwendter A2, Oberaigner W3, Hintringer K4, Endel G5, Siebert U6
1UMIT - University for Health Sciences, Medical Informatics and Technology/ ONCOTYROL - Center for Personalized Cancer Medicine, Hall in Tyrol/ Innsbruck, Austria, 2Medical University Innsbruck, Innsbruck, Austria, 3Tirol Kliniken Innsbruck, Innsbruck, Austria, 4TGKK-Tyrolean Sickness Fund, Innsbruck, Austria, 5Main Association of Austrian Social Insurance Institutions, Vienna, Austria, 6and Director, Division for HTA, ONCOTYROL – Center for Personalized Cancer Medicine, Hall i.T., Austria

PMD56
B18
COST-EFFECTIVENESS ANALYSIS OF DIAGNOSTICS OF TUBERCULOSIS INFECTION IN THE RUSSIAN FEDERATION WITH THE USE OF TUBERCULOUS RECOMBINANT ALLERGEN
Holownia M, Solodun I, Bashlakova E, Ermolaeva T, Davydovskaya M, Evdoshenko E
State Budgetary Institution of Moscow City «Center of Clinical Trials Management and Performance of Moscow Department of Healthcare», Moscow, Russia

PMD57
B19
THE COST-EFFECTIVENESS OF WHOLE-EXOME SEQUENCING IN COMPLEX PAEDIATRIC NEUROLOGY
van Nimwegen K, Vissers L, Willemsen M, Schieving J, Veltman J, van Der Wilt G, Grutters JP
Radboud university medical center, Nijmegen, The Netherlands

PMD58
B20
COST-EFFECTIVENESS OF SCREENING FOR SEVERE SLEEP-DISORDERED BREATHING IN JAPAN
Takegami M1, Moriwaki K2, Nishimura K1, Miyamoto Y1
1National Cerebral and Cardiovascular Center, Suita, Japan, 2Kobe Pharmaceutical University, Kobe, Japan

PMD59
B21
INVESTIGATING THE COST-EFFECTIVENESS OF GENETIC COUNSELLING FOR COUPLES AT KNOWN RISK OF HAVING CHILDREN WITH TAY-SACHS DISEASE: A TWO-GENERATION MODEL
Ghosh W, Griffiths M, Griffiths A
Costello Medical Consulting Ltd, Cambridge, UK

PMD60
B22
COST-EFFECTIVENESS OF ACTIVE SURVEILLANCE OF BETA-D-GLUCAN IN INTENSIVE CARE UNITS IN HONG KONG
Pang Y, Ip M, You J
The Chinese University of Hong Kong, Shatin, Hong Kong

PMD61
B23
COST-EFFECTIVENESS OF D-DIMER IN THE DIAGNOSIS OF VENOUS THROMBOEMBOLISM IN COLOMBIA
Gil-Rojas Y1, Castañeda-Cardona C2, Rosselli D1
1Pontificia Universidad Javeriana, Bogota, Colombia, 2Neuroeconomix, Bogota, DC, Colombia

PMD62
B24
COST-EFFECTIVENESS ANALYSIS OF TELEMONITORING IN GYNAECOLOGY AND OBSTETRICS
Gajdoš O, Hrubý J
Czech Technical University in Prague, Kladno, Czech Republic

PMD63
B25
SYSTEMATIC REVIEW OF COST-EFFECTIVENESS ANALYSIS (CEA) OF THE CELL FREE DNA (CFDNA) / NON-INVASIVE PRENATAL TEST (NIPT) FOR TRISOMY 21 (T21) SCREENING
Bourdoncle M1, Li J2, Berthelot A2, Cognet M3, Sambuc C3, Scemama O3, Rumeau-Pichon C3
1CHU Toulouse, Toulouse, France, 2Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France, 3Haute Autorité de Santé (HAS), Saint-Denis La Plaine, France

PMD64
B26
COST-EFFECTIVENESS OF TEST STRIPS FOR GLUCOSE MONITORING
Martin Saborido C, Antón Rodriguez C, Monge Martín D
Universidad Francisco de Vitoria, Pozuelo de Alarcón, Spain

PMD65
B27
FAECAL CALPROTECTIN AS A DIAGNOSTIC MARKER OF INFLAMMATORY BOWEL DISEASE IN PATIENTS WITH GASTROINTESTINAL SYMPTOMS - IS IT COST-EFFECTIVE PROCEDURE IN PRIMARY CARE IN POLAND?
Petryszyn P1, Trznadel A1, Staniak A1, Well M2, Ekk-Cierniakowski P3
1Wroclaw Medical University, Wroclaw, Poland, 2Wroclaw Uiversity of Economics, Wroclaw, Poland, 3Warsaw School of Economics, Warsaw, Poland

PMD66
B28
VALUE OF IMPROVED ACCURACY FOR SELF-MONITORING OF BLOOD GLUCOSE DEVICES IN GERMANY
McQueen RB1, Breton M2, Ott M3, Campbell JD4
1University of Colorado, Aurora, CO, USA, 2University of Virginia, Charlottesville, CO, USA, 3Ascensia Diabetes Care, Leverkusen, Germany, 4University of Colorado Anschutz Medical Campus, Denver, CO, USA

PMD67
B29
COST-EFFECTIVENESS OF A PREVENTIVE TESTING STRATEGY IN RELATIVES OF PATIENTS WITH BRCA MUTATED OVARIAN CANCER VERSUS A NO TEST STRATEGY
Cicchetti A1, Ruggeri M2, Di Brino E3
1Catholic University of Sacred Heart, Rome, Italy, 2ALTEMS, Università Cattolica del Sacro Cuore (UCSC), Postgraduate School of Health Economics and Management, Rome, Italy, 3ALTEMS (Post-graduate School of Health Economics and Management), Catholic University of the Sacred Heart, Roma, Italy

PMD68
B30
COST-EFFECTIVENESS ANALYSIS OF SERUM FREE LIGHT CHAIN ASSAY (FREELITE®) FOR THE DIAGNOSIS OF MONOCLONAL GAMMOPATHY IN THE BRAZILIAN PUBLIC AND PRIVATE HEALTHCARE SYSTEMS
Riveros BS1, Caporal F1, Soares E2, Facco F2
1Federal University of Parana, Curitiba, Brazil, 2The Binding Site, Curitiba, Brazil

PMD69
B31
WHAT IS THE MOST COST-EFFECTIVE WAY TO SET-UP ORGANISED CERVICAL CANCER SCREENING IN FRANCE? A COST-EFFECTIVENESS ANALYSIS
Massetti M1, Leleu H2, Barre S3, De Bels F3
1PUBLIC HEALTH EXPERTISE, Paris, France, 2Public Health Expertise, Paris, France, 3French Cancer Institut, Boulogne, France

PMD70
B32
ASSESSING THE COST-EFFECTIVENESS OF TRANSCATHETER AORTIC VALVE IMPLANTATION IN INOPERABLE PATIENTS WITH SEVERE AORTIC STENOSIS IN UK
Ramos M1, Lamotte M1, Chevalier P1, Goodall G2
1IMS Health, Zaventem, Belgium, 2Edwards Lifesciences, Nyon, Switzerland

PMD71
B33
COST-EFFECTIVENESS OF SEQUENTIAL USE OF ELF/ARFI TEST VERSUS BIOPSY TO ASSESS LIVER FIBROSIS IN CHRONIC HCV
Soto M1, Sampietro-Colom L1, Lasalvia L2, Jimenez W3, Mira A3, Navasa M3
1Hospital Clínic Barcelona, Barcelona, Spain, 2Siemens Healthcare, Tarrytown, NY, USA, 3Hospital Clinic Barcelona, Barcelona, Spain

PMD72
B34
DEEP BRAIN STIMULATION COMPARED TO DEVICE-AIDED INFUSION THERAPIES FOR PARKINSON’S DISEASE WITH EARLY MOTOR COMPLICATIONS: A UK COST-EFFECTIVENESS ANALYSIS
Green AL1, Fundament T2
1University of Oxford, Oxford, UK, 2HTA Consulting, Krakow, Poland

PMD73
B35
COST-EFFECTIVENESS OF MECHANICAL THROMBECTOMY USING STENT-RETRIEVER AFTER INTRAVENOUS T-PA COMPARED WITH INTRAVENOUS T-PA ALONE IN THE TREATMENT OF ACUTE ISCHEMIC STROKE DUE TO LARGE VESSEL OCCLUSION IN SPAIN
de Andrés-Nogales F1, Álvarez M2, de Miquel MÁ3, Segura T4, Gil A5, Cardona P3, Casado MÁ1, Nogueira RG6, Dávalos A7
1Pharmacoeconomics & Outcomes Research Iberia, Pozuelo de Alarcón (Madrid), Spain, 2Medtronic Ibérica, S.A., Madrid, Spain, 3Hospital Univeritari de Bellvitge, L'Hospitalet de Llobregat, Spain, 4Complejo Hospitalario Universitario de Albacete, Albacete, Spain, 5Hospital Universitario de Cruces, Barakaldo, Spain, 6Emory University School of Medicine, Atlanta, GA, USA, 7Hospital Universitari Germans Trias i Pujol, Badalona, Spain

PMD74
B36
COST EFFECTIVENESS ANALYSIS OF A FLASH GLUCOSE MONITORING SYSTEM FOR TYPE 1 DIABETES (T1DM) PATIENTS RECEIVING INTENSIVE INSULIN TREATMENT IN EUROPE AND AUSTRALIA
Bilir SP1, Li H2, Wehler EA3, Hellmund R4, Munakata J1
1IMS Health, San Francisco, CA, USA, 2IMS Health, Fairfax, VA, USA, 3IMS Health, Plymouth Meeting, PA, USA, 4Abbott Diabetes Care, Alameda, CA, USA

PMD75
B37
COST EFFECTIVENESS ANALYSIS OF A FLASH GLUCOSE MONITORING SYSTEM FOR TYPE 2 DIABETES (T2DM) PATIENTS RECEIVING INTENSIVE INSULIN TREATMENT IN EUROPE
Li H1, Bilir SP2, Wehler EA3, Hellmund R4, Munakata J2
1IMS Health, Fairfax, VA, USA, 2IMS Health, San Francisco, CA, USA, 3IMS Health, Plymouth Meeting, PA, USA, 4Abbott Diabetes Care, Alameda, CA, USA

PMD76
B38
A PRELIMINARY COST-UTILITY ANALYSIS OF NON-INVASIVE VAGUS NERVE STIMULATION THERAPY IN PATIENTS SUFFERING WITH HEADACHE AND FUNCTIONAL DISORDER MULTI-MORBIDITY
Jenks M1, Davis S2, Amato F3, Errico J3, Strickland I3
1York Health Economics Consortium, York, UK, 2Interface Clinical Services, Leeds, UK, 3electroCore LLC, Basking Ridge, NJ, USA

PMD77
C1
COST-EFFECTIVENESS ANALYSIS OF USING PROCALCITONIN-BASED ANTIBIOTICS STEWARDSHIP FOR COMMUNITY ACQUIRED PNEUMONIA
Hsu W1, Lee S1, Lee MG1, Lee C2
1National Taiwan University Hospital, Taipei City, Taiwan, 2National Taiwan University Hospital, Yunlin Branch, Douliou, Taiwan

PMD78
C2
COMPARISON OF MIRENA INTRAUTERINE DEVICE WITH ORAL PROGESTERONE TREATMENT AND SURGICAL TREATMENT IN IDIOPATHIC MENORRHAGIA PATIENTS: RESULTS OF A COST-MINIMISATION ANALYSIS
Buyuktuna N, Sumer F, Erdal E
Bayer Turk Kimya San. Ltd. Sti., Istanbul, Turkey

PMD79
C3
SPINAL CORD STIMULATION VERSUS CONVENTIONAL MEDICAL MANAGEMENT FOR FAILED BACK SURGERY SYNDROME: A DUTCH COST-EFFECTIVENESS ANALYSIS
Huygen FJ1, Eggington S2, De Brouwer BF3
1University Hospital Erasmus Medical Centre, Rotterdam, The Netherlands, 2Medtronic International Trading Sarl, Tolochenaz, Switzerland, 3Medtronic Trading NL BV, Heerlen, The Netherlands

PMD80
C4
HEALTH-ECONOMIC ANALYSIS OF THE USE OF SENSOR-AUGMENTED PUMP WITH PREDICTIVE SUSPEND FUNCTION (SAP) THERAPY IN SWEDEN COMPARED TO INSULIN PUMP THERAPY ALONE (CSII), IN TYPE 1 DIABETIC PATIENTS
Roze S1, Gherardi A1, de Portu S2, Jendle J3
1HEVA HEOR Sarl, Lyon, France, 2Medtronic International Sàrl, Tolochenaz, Switzerland, 3Örebro University, Örebro, Sweden

PMD81
C5
COST UTILITY ANALYSIS OF MONITORING OSTEOPOROSIS FRACTURE RISK BY A CIRCULATING MICRORNA BASED STRATEGY COMPARED TO STANDARD MEASURE AND NO MONITORING
Walter E1, Grillari J2, Kanzler O3, Hackl M3
1Institute for Pharmaeconomic Research, Vienna, Austria, 2University of Natural Resources and Life Sciences, Vienna, Austria, 3TAmiRNA GmbH, Vienna, Austria

PMD82
C6
COST-UTILITY OF IN-AMBULANCE TELEMEDICINE FOR SUSPECTED STROKE PATIENTS
Valenzuela Espinoza A1, Devos S1, Van Hooff R2, Fobelets M1, Dupont A3, Brouns R2, Putman K1
1Vrije Universiteit Brussel, Brussels, Belgium, 2Universitair Ziekenhuis Brussel, Brussels, Belgium, 3Vrije Universiteit Brussel, Brussel, Belgium

PMD83
C7
COST-EFFECTIVENESS OF DIAGNOSTIC TESTS FOR PEOPLE AT RISK OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IN THE UK
Floros L1, Day C2, Wonderling D1, Glen J1, Harker M1
1Royal College of Physicians, London, UK, 2Faculty of Medical Sciencies, Newcastle University, Newcastle, UK

PMD84
C8
USE OF SUTURELESS PROSTHESIS NEUTRALIZES EXPECTED WORSE ECONOMIC IMPACT OF HIGH RISK PATIENTS UNDERGOING AORTIC VALVE REPLACEMENT
Villa E, Trenta A, Dalla Tomba M, Messina A, Brunelli F, Cirillo M, Mhagna Z, Valerio M, Troise G
Poliambulanza Foundation Hospital, Brescia, Italy

MEDICAL DEVICE/DIAGNOSTICS - Patient-Reported Outcomes & Patient Preference Studies
PMD85
C9
USING A SMARTPHONE BASED SELF-MANAGEMENT PLATFORM TO SUPPORT MEDICATION ADHERENCE AND CLINICAL CONSULTATION IN PARKINSON’S DISEASE RESULTS FROM THE SMART-PD RANDOMISED CONTROLLED TRIAL
Lakshminarayana R1, Wang D2, Burn D3, Chaudhuri KR4, Hellman B1, SMART-PD Investigators I1
1uMotif, London, UK, 2Liverpool School of Troical Medicine, Liverpool, UK, 3Newcastle-upon-Tyne Hospitals NHS Foundation Trust, UK, Newcastle University, UK, 4King's College Hospital NHS FOundation Trust, London, UK

PMD86
C10
FROM THE UNIFIED PARKINSON’S DISEASE RATING SCALE (UPDRS) TO THE EQ-5D UTILITY INDEX: DEVELOPMENT OF A NEW MAPPING ALGORITHM IN PARKINSON’S DISEASE (PD)
Grifi M1, Gorecki M2, Schuepbach M3
1Medtronic International, Tolochenaz, Switzerland, 2HTA Consulting, Krakow, Poland, 3CHU Pitié-Salpêtrière, paris, France

PMD87
C11
GENERATING HEALTH UTILITY VALUES FROM US SF-36 SCORES FOR FRENCH ASSESSMENT: COMPARISON OF 3 MAPPING METHODS
Baschet L, Grassi V, Levesque K
Capionis, Bordeaux, France

PMD88
C12
BENEFITS OF AN AUTOMATIC TOOL FOR GLUCOSE PATTERN DETECTION
Comellas MJ1, Albiñana E2, Artés M3, Corcoy R4, Fernández-García D5, García-Alemán J5, García-Cuartero B6, González C4, Rivero M7
1Roche Diabetes Care Spain SL, Barcelona, Spain, 2Vithas Hospital Internacional Medimar, Alicante, Spain, 3Adelphi Spain, Barcelona, Spain, 4Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 5Hospital Universitario Virgen de la Victoria, Málaga, Spain, 6Hospital Ramón y Cajal, Madrid, Spain, 7Complejo Hospitalario de Orense, Orense, Spain

PMD89
C13
BEHAVIOR OF VAS MEASURES OF PATIENT SATISFACTION WITH REMOTE MONITORING OF CARDIAC IMPLANTABLE ELECTRONIC DEVICES. THE VALIOSA QUESTIONNAIRE
Ruiz MA1, Egea M2, Muñoz R3, Viñolas X4, Silvestre J5, Álvarez M6, Martínez-Ferrer JB7
1Universidad Autónoma de Madrid, Madrid, Spain, 2Medtronic Iberica, Madrid, Spain, 3Hospital Universitario Infanta Leonor, Madrid, Spain, 4Hospital Santa Creu i Sant Pau, Barcelona, Spain, 5Hospital Universitario La Paz, Madrid, Spain, 6Medtronic Ibérica, Madrid, Spain, 7Hospital Universitario Araba, Vitoria, Spain

PMD90
C14
AUTOINJECTOR PREFERENCE AMONG PATIENTS WITH MULTIPLE SCLEROSIS: RESULTS FROM A NATIONAL SURVEY
Schreiner T1, Reischl J1, Mann B2, Morosov X1, Kokoschka A1, Weller I1
1Bayer Vital GmbH, Leverkusen, Germany, 2IFAK Institut GmbH & Co. KG, Taunusstein, Germany

PMD91
C15
IMPROVING PATIENTS QUALITY OF LIFE BY VALUATION OF PATIENT SATISFACTION WITH SPECIFIC CHARACTERISTICS OF REHABILITATION MEDICAL DEVICES - WEIGHT, FIT, APPEARANCE, COMFORT, PAIN FREE, FREE OF ABRASIVENESS, EASE OF APPLICATION AND DURABILITY
Malovecka I1, Minarikova D1, Minarik P2, Foltan V1
1Comenius University, Faculty of Pharmacy, Bratislava, Slovak Republic, 2College of Health and Social Work St. Elizabeth, Bratislava, Slovakia

PMD92
C16
WHICH MEDICAL DEVICE FOR URINARY INCONTINENCE PROVIDES PATIENT THE HIGHER QUALITY OF LIFE?
Minarikova D1, Malovecka I1, Minarik P2, Fazekas T3, Szucs G4
1Comenius University, Faculty of Pharmacy, Bratislava, Slovak Republic, 2College of Health and Social Work St. Elizabeth, Bratislava, Slovakia, 3Comenius University, Faculty of Pharmacy, Bratislava, Slovakia, 4Comenius University, Faculty of Mathematics, Physics and Informatics, Bratislava, Slovakia

PMD93
C17
PATIENT REPORTED OUTCOMES - PATIENT SATISFACTION WITH SELECTED CHARACTERISTICS OF REHABILITATION MEDICAL DEVICES - USAGE, ACQUISITION, OFFER, RANGE AND QUALITY
Malovecka I1, Minarikova D1, Fazekas T2, Szucs G3
1Comenius University, Faculty of Pharmacy, Bratislava, Slovak Republic, 2Comenius University, Bratislava, Slovak Republic, 3Comenius University, Faculty of Mathematics, Physics and Informatics, Bratislava, Slovakia

PMD94
C18
COMPARATIVE EXPLORATORY ANALYSIS ON EFFECTIVENESS, TOLERABILITY AND PATIENT/NURSE SATISFACTION WITH TWO NON-INVASIVE PATIENT CONTROLLED ANALGESIA TREATMENTS FOR ACUTE POST-OPERATIVE PAIN MANAGEMENT
Katz P1, Takyar S2, Palmer PP3, DiDonato K3, Liedgens H1
1Grünenthal GmbH, Aachen, Germany, 2PAREXEL International, Chandigarh, India, 3AcelRx Pharmaceuticals, Inc., Redwood City, CA, USA

PMD95
C19
THE CURRENT STATUS AND INFLUENTIAL FACTORS OF INSULIN PEN NEEDLE REUSE IN T2D PATIENTS FROM CHINA
Han S, Guan XD, Shi LW
International Research Center of Medical Administration, Peking University, Beijing, China

PMD96
C20
IMPROVING PATIENTS QUALITY OF LIFE BY VALUATION OF PATIENT SATISFACTION WITH SPECIFIC CHARACTERISTICS OF MEDICAL DEVICES FOR URINARY INCONTINENCE
Minarikova D1, Malovecka I2, Minarik P3
1Comenius University, Faculty of Pharmacy, Bratislava, Slovak Republic, 2Comenius University, Bratislava, Slovak Republic, 3College of Health and Social Work St. Elizabeth, Bratislava, Slovakia

PMD97
WITHDRAWN

PMD98
C21
NON-INVASIVE VAGUS NERVE STIMULATION AS A TREATMENT FOR HEADACHE PATIENTS WITH MULTI-MORBIDITY: REAL WORLD EXPERIENCE IN ENGLISH PRIMARY CARE
Strickland I1, Davis S2, Ward J3, Amato F1, Errico J1
1electroCore LLC, Basking Ridge, NJ, USA, 2Interface Clinical Services, Leeds, UK, 3Oaklands Health Centre, Holmfirth, UK

PMD99
C22
ACCEPTABILITY OF ELECTRONIC PATIENT REPORTED OUTCOMES IN CLINICAL CARE OF HIV
Duracinsky M1, Jouannigot J2, Grace A3, Power B4, Desai R4, Lalanne C2, Herrmann S3, Chassany O2
1Assistance Publique-Hopitaux de Paris, Paris, France, 2University Paris-Diderot, Sorbonne Paris Cité, Paris, France, 3Murdoch University, Murdoch, Australia, 4e) School of Arts Murdoch University, Murdoch, Australia

MEDICAL DEVICE/DIAGNOSTICS - Health Care Use & Policy Studies
PMD100
C23
THE INCREASING ROLE OF WEARABLE DIGITAL TECHNOLOGY IN DISEASE MANAGEMENT - AN ASSESSMENT OF THE OPPORTUNITIES AND CHALLENGES FROM A MULTI-STAKEHOLDER (PATIENT, PAYER, PHYSICIAN, MANUFACTURER) PERSPECTIVE
Entwistle J, Okoye J, Teale CW, Tombrink H, Kleebach J
GfK, Melton Mowbray, UK

PMD101
C24
THE EFFECTS OF CONTINUES GLUCOSE MONITORING SYSTEM ON PATIENT OUTCOMES AND ASSOCIATED COSTS
Fund N1, Azuri J2, Levi L1, Porath A1, Triki N1
1Maccabi Healthcare Services, Tel-Aviv, Israel, 2Tel Aviv University, Tel Aviv, Israel

PMD102
C25
A DYNAMIC SIMULATION TO INVESTIGATE HEALTH ECONOMIC IMPACT OF A PULMONARY ARTERY PRESSURE SENSOR FOR HEART FAILURE TELEMONITORING
Kolominsky-Rabas P1, Kriza C2, Uffenorde S3, Zhang S4, Gaiser S5
1Interdisciplinary Centre for Health Technology Assessment and Public Health (IZPH), Friedrich-Alexander-University of Erlangen-Nürnberg; National Leading-Edge Cluster Medical Technologies ‘Medical Valley EMN’, Erlangen, Germany, 2Interdiciplinary Centre for Health Technology Assessment and Public Health (IZPH), Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany, 3St Jude Medical GmbH, Eschborn, Germany, 4Interdisciplinary Centre for Health Technology Assessment and Public Health (IZPH), Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany, 5St Jude Medical, Zaventem, Belgium

PMD103
C26
VARIATION IN THE NUMBER AND TYPE OF HEART VALVE PROCEDURES PERFORMED IN THE UK – IS PATIENT ACCESS EQUITABLE?
Murphy J1, Goodall G2
1Edwards Lifesciences, Newbury, UK, 2Edwards Lifesciences, Nyon, Switzerland

PMD104
C27
THE ASSESSMENT OF VALUE FOR MEDICAL DEVICES: USING REAL WORLD EVIDENCE (RWE) TO QUANTIFY UNMET NEEDS IN DIABETES MANAGEMENT
Charter R1, Yeung A2, Smith M2, Hopley C3
1Becton Dickinson AG, Allschwil, Switzerland, 2Becton Dickinson (BD), Allschwil, Switzerland, 3Becton Dickinson, Oxford, Switzerland

PMD105
C28
SPATIAL DISTRIBUTION OF THE TOTAL NUMBER OF MEDICAL DEVICES IN TURKEY: A CLASSIFICATION ANALYSIS
Cinaroglu S1, Baser O2
1Hacettepe University, Ankara, Turkey, 2Columbia University/MEF University/STATinMED Research, New York, NY, USA

PMD106
C29
REGIONAL MARKET ACCESS PATHWAYS FOR DIAGNOSTICS IN ITALY
Mantuano M, Urbinati D, Daniel F, Tettamanti A
IMS Health, Milano, Italy

PMD107
C30
CRITERIA USED BY GERMAN PULMONOLOGISTS FOR THE SELECTION OF AN INHALER
Schwarz E1, Redeker M1, Mohrlang C1, Andres J2, Hellmann A3, Hering T4, Hering T2
1GlaxoSmithKline GmbH & Co. KG, München, Germany, 2Wissenschaftliches Netzwerk des Bundesverbandes der Pneumologen/BdP (WinPneu), Heidenheim, Germany, 3Zentrum für Pneumologie, Onkologie und Schlafmedizin am Diako, Augsburg, Germany, 4Lungenarztpraxis Tegel, Berlin, Germany

PMD108
C31
WHEN COST SAVING TECHNOLOGIES ARE NOT ADOPTED DESPITE EVIDENCE AND PAYER RECOMMENDATIONS – INTRAOPERATIVE FLUID MANAGEMENT (IOFM) IN THE UK
Murphy J1, Goodall G2
1Edwards Lifesciences, Newbury, UK, 2Edwards Lifesciences, Nyon, Switzerland

PMD109
C32
HEALTHCARE EXPENDITURES AND EQUITY IN HEALTHCARE UTILIZATION FOR LYMPHEDEMA PATIENTS IN FRANCE
Mercier G1, Pastor JZ1, Clement V2, Rodts U1, Quere I1
1CHU Montpellier, Montpellier, France, 2Universite de Montpellier, Montpellier, France

PMD110
C33
SURGICAL SITE COMPLICATIONS: TO PREVENT OR NOT TO PREVENT? A BUDGET IMPACT ANALYSIS IN THE HOSPITAL SETTING
Foglia E1, Ferrario L1, Canonico S2, Signoriello G3, Pellino G2, Croce D1
1LIUC University, Castellanza, Italy, 2School of Medicine, Second University of Naples, Napoli, Italy, 3Department of Medicine and Public Health, Second University of Naples, Napoli, Italy

PMD111
C34
COST-BENEFIT ANALYSIS: A COMPARISON BETWEEN PRESET ARTERY BLOOD SAMPLERS AND DISPOSABLE SYRINGES IN ARTERIAL BLOOD SAMPLING
Gao M1, Wang Y2, Wang J3, Zeng F4, Yang Q5, Ren X5
1The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, 2Shanghai Tenth People’s Hospital, Shanghai, China, 3China-Japan Friendship Hospital, Beijing, China, 4The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China, 5Becton Dickinson Medical Devices (Shanghai) Co Ltd., Shanghai, China

PMD112
C35
SYSTEMATIC REVIEW OF THE VALUE OF SAFETY-ENGINEERED DEVICES IN REDUCING NEEDLESTICK AND SHARPS INJURIES
Shang Y1, Ren X2
1Shenyang Pharmaceutical University, Shenyang, China, 2Becton Dickinson Medical Devices (Shanghai) Co Ltd., Beijing, China

PMD113
C36
A TIME SERIES ANALYSIS OF SOCIAL INSURANCE AND PATIENT COSTS OF REIMBURSED MEDICAL AIDS IN HUNGARY
Takacs G
National Institute of Pharmacy and Nutrition, Budapest, Hungary

PMD114
C37
A MODELED HEALTH ECONOMIC ANALYSIS OF THE ACCUCATH® INTRAVASCULAR CATHETER SYSTEM WITH RETRACTABLE COILED TIP GUIDEWIRE COMPARED WITH CONVENTIONAL PERIPHERAL INTRAVASCULAR CATHETERS
Kara R1, Hollmann S2, Ferko N2, Delatore P3
1Bard Access Systems, Salt Lake City, UT, USA, 2Cornerstone Research Group Inc., Burlington, ON, Canada, 3CR Bard Inc., Murray Hill, NJ, USA

PMD115
C38
THE SITUATE DETECTION SYSTEM - A COST-EFFECTIVE APPROACH TO PREVENTING RETAINED SURGICAL SPONGES
Leinwand B, Hughes KE
Avalere Health LLC, Washington, DC, USA

PMD116
D1
IS BIG DATA IN HEALTHCARE ABOUT BIG HOPE OR BIG HYPE? EARLY HEALTH TECHNOLOGY ASSESSMENT OF BIG DATA ANALYTICS IN HEALTHCARE
Bakker LJ1, Aarts J2, Redekop WK3
1institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands, 2University at Buffalo, Buffalo, NY, USA, 3Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands

PMD117
D2
PERIOPERATIVE THERAPIES REDUCING HOMOLOGOUS TRANSFUSIONS DURING CARDIOVASCULAR SURGERY: A NETWORK META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Pradelli L1, Povero M1, Myers G2
1AdRes Srl, Torino, Italy, 2Eastern Perfusion International, Dartmouth, NS, Canada

PMD118
D3
IMPACT OF WHOLE EXOME SEQUENCING (WES) ON COSTS AND MEDICAL DECISION-MAKING
Middelburg P1, Monroe G2, van Gassen K2, Hovels A1, Knoers N2, Vrijenhoek T2, Frederix G2
1Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands, 2University Medical Centre Utrecht, Utrecht, The Netherlands

PMD119
D4
SUBSTITUTABILITY OF DRY POWDER INHALERS: A PERSPECTIVE FROM GERMAN PULMONOLOGISTS
Redeker M1, Schwarz E1, Mohrlang C1, Hellmann A2, Hering T3, Hering T4, Andres J3
1GlaxoSmithKline GmbH & Co. KG, München, Germany, 2Zentrum für Pneumologie, Onkologie und Schlafmedizin am Diako, Augsburg, Augsburg, Germany, 3Wissenschaftliches Netzwerk des Bundesverbandes der Pneumologen/BdP (WinPneu), Heidenheim, Germany, 4Lungenarztpraxis Tegel, Berlin, Germany

PMD120
D5
ARE CRITERIA COMMONLY USED IN THE BENEFIT ASSESSMENT OF DRUGS ALSO APPLICABLE TO MEDICAL DEVICES? - A SYSTEMATIC LITERATURE REVIEW
Stephan M, Sauer A, Günzel F, Italia N, Kulp W
Xcenda GmbH, Hannover, Germany

PMD121
D6
NEW LEGISLATIVE PATHWAY OF TURKEY FOR ASSESSING REIMBURSEMENT APPLICATONS OF MEDICAL DEVICES
Ozdiler Copur F, Akgul T, Ozdemir Saltik Z, Can H, Askin E
Medtronic, Istanbul, Turkey

PMD122
D7
A NEW ACCELERATED EARLY ACCESS PROCESS FOR DIAGNOSTICS IN FRANCE
Hanna E, Azaiez C, Auquier P, Toumi M
Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille, France

PMD123
D8
COST-EFFECTIVENESS ANALYSIS OF SCREENING STRATEGIES FOR ATRIAL FIBRILLATION IN ENGLAND AND WALES
Thom H1, Hollingworth W1, McAleenan A1, Davies P1, Higgins J1, Okoli GN1, Sterne J1, Feder G1, Eaton D2, Hingorani A3, Fawsitt C1, Lobban T4, Bryden PA5, Richards A1, Sofat R3, Welton NJ1
1University of Bristol, Bristol, UK, 2Anticoagulation Europe, Kent, UK, 3University College London, London, UK, 4Atrial Fibrillation Association, Warwickshire, UK, 5Roche, Basel, Switzerland

PMD124
D9
ANALYSIS OF HTA REQUIREMENTS ACROSS 10 EMERGING AND DEVELOPED COUNTRIES
Hertz D, Vazquez V, Gavaghan M
GfK, Wayland, MA, USA

PMD125
D10
INFLUENCE OF MEDICAL–ECONOMIC ANALYSIS ON THE CATEGORIZATION OF SPECIAL MEDICAL EQUIPMENT
Lehocka L, Masarykova L, Snopkova M, Bohusova S
Comenius University in Bratislava, Faculty of Pharmacy, Bratislava, Slovakia

PMD126
D11
EFFICIENCY IN USE OF LENSX VS PHACOEMULSIFICATION SURGERY FOR CATARACT TREATMENT: RESULTS FROM A GLOBAL OBSERVATIONAL STUDY
Keith MS1, Becker G2, Bayer S2
1Alcon Laboratories, Inc, Fort Worth, TX, USA, 2Q-Perior AG, Zurich, Switzerland

PMD127
D12
BENEFIT ASSESSMENT OF MEDICAL DEVICES OF HIGH RISK CLASSES IN GERMANY: ADAPTIVE APPROACHES TO BALANCE EARLY ACCESS AND SAFETY AND EFFICACY REQUIRED?
Mühlbacher AC, Juhnke C, Mörk V
Hochschule Neubrandenburg, Neubrandenburg, Germany

PMD128
D13
ADOPTION OF ENDOSCOPIC LUNG VOLUME REDUCTION FOR EMPHYSEMA IN GERMANY: UTILIZATION PATTERNS AND CASE VOLUMES IN THE PERIOD 2010-2014
Busca R1, Rott C1, Pietzsch JB2, Herth F3
1PneumRx Ltd, London, UK, 2Wing Tech Inc., Irvine, CA, USA, 3Thoraxklinik University of Heidelberg, Heidelberg, Germany

PMD129
D14
CURRENT STATUS OF ENDOSCOPIC SUBMUCOSAL DISSECTION TREATMENT FOR GASTRIC ADENOMA IN KOREA: BASED ON NATIONAL CLAIMS DATABASE
Cha Y1, Kim J1, Lee NR2, Lyu DH2, Park C2
1National evidence-based health care Collaborating Agency, Korea, Seoul, South Korea, 2National Evidence-based Healthcare Collaborating Agency, Seoul, South Korea

Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.